Targets › CLEC4C
2 programs from 2 companies in 4 trials: 2 Phase 3, 1 Phase 2, 1 Phase 1; Immunology; next expected readout Mar 2027.
Lectin-type cell surface receptor which may play a role in antigen capturing by dendritic cells. Specifically recognizes non-sialylated galactose-terminated biantennary glycans containing the trisaccharide epitope Gal(beta1-3/4)GlcNAc(beta1-2)Man. (UniProt, Q8WTT0)
Open in Phaseline: the race on CLEC4C, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Biogen | Litifilimab (BIIB059) C-type lectin domain family 4 member C inhibitor | CLEC4C | Phase 3 | Lupus Erythematosus, Systemic; Subacute Cutaneous Lupus Erythematosus | Mar 2027 |
| Biocad | Litifilimab (BCD-256) C-type lectin domain family 4 member C inhibitor | CLEC4C | Phase 1 | Systemic Lupus Erthematosus | – |
Lupus Erythematosus, Systemic (2) Subacute Cutaneous Lupus Erythematosus (1) Systemic Lupus Erthematosus (1)
antibody (1), mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.